非布司他用于预防小细胞肺癌化疗后急性肿瘤溶解综合征效果观察  

Effect of Bustard on Prevention of Acute Tumor Lysis Syndrome after Chemotherapy in Small Cell Lung Cancer

作　　者：连爽 LIAN Shuang(Department of Oncology,Panjin Central Hospital,Panjin 124000,Liaoning Province,China)

机构地区：[1]盘锦市中心医院肿瘤内科,辽宁盘锦124000

出　　处：《中国实用乡村医生杂志》2021年第2期59-61,65,共4页Chinese Practical Journal of Rural Doctor

摘　　要：目的探讨非布司他用于预防小细胞肺癌(SCLC)化疗期间出现急性肿溶解综合征(ATLS)的效果.方法收集2016—2020年盘锦市中心医院收治的SCLC化疗患者50例,随机分为对照组和观察组各25例.两组患者分别于化疗前1 d开始口服药物预防ATLS出现,对照组采用别嘌醇,对照组采用非布司他.比较两组患者用药前后不同时间点血尿酸(SUA)、肌酐(Scr)和尿素氮(BUN)变化情况,及化疗前期间ATLS发生情况.结果两组患者D0时间点SUA、Scr、BUN差异无统计学意义(P>0.05);经治疗后,D_(1)时间点SUA、Scr、BUN呈增加趋势,D_(2)和D_(3)时间点SUA、Scr、BUN呈下降趋势,两组患者D_(1)、D_(2)、D_(3)时间点SUA、Scr、BUN差异有统计学意义(P<0.05).化疗期间对照组ATLS发生率为24.00%;观察组ATLS发生率为4.00%,差异有统计学意义(P<0.045).结论非布司他能够进一步控制SCLC患者化疗期间血尿酸水平,并且有效保护患者肾脏功能,减少ATLS的发生.Objective To investigate the effect of febuxostat in the prevention of acute tumor lysis syndrome(ATLS)during chemotherapy in small cell lung cancer(SCLC).Methods A total of 50 patients with SCLC chemotherapy in our hospital from 2016 to 2020 were randomly divided into control group and observation group with 25 cases in each group.Both groups were given oral medicine to prevent ATLS at one day before chemotherapy.Allopurinol was used in the control group,and febuxostat was used in the observation group.The changes of serum uric acid(SUA),creatinine(SCR)and urea nitrogen(BUN)at different time points before and after treatment were compared between the two groups,as well as the occurrence of ATLS before and after chemotherapy.Results There was no significant difference in SUA,SCR and BUN between the two groups at dO time point(P>0.05);after treatment,SUA,SCR and BUN showed an increasing trend at D_(1)time point,while SUA,SCR and BUN at D_(2) and D_(3) time points showed a downward trend.There were significant differences in SUA,SCR and BUN between the two groups at D_(1),D_(2),D_(3) time points(P<O.O5).During chemotherapy,the incidence of ATLS in the control group was 24.00%,and that in the observation group was 4.00%,the difference was significant(P<0.05).Conclusion Febuxostat can further control the level of serum uric acid in patients with SCLC during chemotherapy,and effectively protect the renal function and reduce the occurrence of ATLS in SCLC patients.

关 键 词：小细胞肺癌 急性肿瘤溶解综合征 非布司他 别嘌醇 预防 

分 类 号：R734.2[医药卫生—肿瘤]